Correlation Between Arcus Biosciences and Vaccinex
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Vaccinex at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Vaccinex into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Vaccinex, you can compare the effects of market volatilities on Arcus Biosciences and Vaccinex and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Vaccinex. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Vaccinex.
Diversification Opportunities for Arcus Biosciences and Vaccinex
-0.04 | Correlation Coefficient |
Good diversification
The 3 months correlation between Arcus and Vaccinex is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Vaccinex in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaccinex and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Vaccinex. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaccinex has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Vaccinex go up and down completely randomly.
Pair Corralation between Arcus Biosciences and Vaccinex
Given the investment horizon of 90 days Arcus Biosciences is expected to generate 0.42 times more return on investment than Vaccinex. However, Arcus Biosciences is 2.36 times less risky than Vaccinex. It trades about 0.02 of its potential returns per unit of risk. Vaccinex is currently generating about -0.05 per unit of risk. If you would invest 1,522 in Arcus Biosciences on October 2, 2024 and sell it today you would lose (39.50) from holding Arcus Biosciences or give up 2.6% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 99.56% |
Values | Daily Returns |
Arcus Biosciences vs. Vaccinex
Performance |
Timeline |
Arcus Biosciences |
Vaccinex |
Arcus Biosciences and Vaccinex Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Arcus Biosciences and Vaccinex
The main advantage of trading using opposite Arcus Biosciences and Vaccinex positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Vaccinex can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaccinex will offset losses from the drop in Vaccinex's long position.Arcus Biosciences vs. Cullinan Oncology LLC | Arcus Biosciences vs. Annexon | Arcus Biosciences vs. Structure Therapeutics American | Arcus Biosciences vs. Relay Therapeutics |
Vaccinex vs. Protara Therapeutics | Vaccinex vs. Monopar Therapeutics | Vaccinex vs. Surrozen | Vaccinex vs. Salarius Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |